{"nctId":"NCT00939029","briefTitle":"Highdose Nicotine Patch Therapy for Smokeless Tobacco Use","startDateStruct":{"date":"2010-07"},"conditions":["Smokeless Tobacco Use"],"count":52,"armGroups":[{"label":"Active","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: nicotine replacement therapy (nicotine patches)"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo NRT"]}],"interventions":[{"name":"nicotine replacement therapy (nicotine patches)","otherNames":[]},{"name":"placebo NRT","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. are at least 18 years of age and at most 55 years of age;\n2. report daily ST use for the past 12 months;\n3. identify ST as their primary tobacco product;\n4. use an average of â‰¥ 3 cans/pouches per week;\n5. are in general good health (determined by medical history and screening physical examination);\n6. have been provided with, understand, and have signed the informed consent.\n\nExclusion Criteria:\n\n1. are currently using (past 30 days) any other behavioral or pharmacologic tobacco treatment program;\n2. are currently pregnant or lactating;\n3. have had unstable angina, myocardial infarction, or coronary angioplasty within the past 3 months;\n4. have a history of arrhythmia or an abnormal tracing on the baseline EKG;\n5. have a blood pressure of greater than 140/90 or a pulse of more than 110 beats per minute;\n6. have a history of severe skin allergies or dermatoses;\n7. have a history of intolerance to nicotine patches;\n8. have another member of their household already participating in this study;\n9. are taking a medication known to interact with nicotine (i.e., clozapine);\n10. are taking any prescription medication for depression or asthma","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"End of Treatment (Week 8) Point Prevalence Abstinence","description":"7 day point prevalence abstinence at the end of treatment, biochemically confirmed by urinary anabasine \\< 2 ng per ml","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Point-prevalence Abstinence at 3 Months","description":"7 day point prevalence abstinence from tobacco at 3 months, biochemically confirmed using urinary anabasine \\< 2 ng per ml","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Point-prevalence Abstinence at 6 Months","description":"7 day point prevalence abstinence from all tobacco at 6 months, biochemically confirmed using urinary anabasine \\< 2 ng per ml.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":25},"commonTop":["patch site reaction","nausea","anxiety","diarrhea","dizziness"]}}}